Low-dose atovaquone for prophylaxis of Pneumocystis jirovecii pneumonia in patients with connective tissue diseases: an open-label, multicentre, single-arm, phase II trial
Abstract
Objectives
Pneumocystis jirovecii pneumonia (PCP) is a life-threatening complication that occurs in immunocompromised individuals, including patients with connective tissue diseases under glucocorticoid treatments. Trimethoprim-sulfamethoxazole (TMP-SMX) and atovaquone 1500 mg/d, the first and one of the second-line prophylactic options of PCP, are often difficult to continue the administration due to side effects or the cost. This trial aimed to investigate the efficacy and safety of low-dose atovaquone (750 mg/d) for prophylaxis of PCP in patients with connective tissue disease who started glucocorticoid treatments.
Methods
This open-label, multicentre, single-arm, phase II trial included patients with connective tissue diseases who were scheduled to start or within 10 days from the initiation of 0.5 mg/kg/d or more of prednisolone or equivalent dose. All patients received low-dose atovaquone for 24 weeks. The primary endpoint was the incidence of PCP at 24 weeks, and adverse events were also assessed as secondary endpoints.
Results
Fifty patients were assigned to receive low-dose atovaquone, and 45 were included in the primary analysis. Thirteen patients (28.9%) had comorbidities of lung diseases, and 33 (73.3%) received one or more immunosuppressants or biologics in addition to glucocorticoids during the trial period. No cases of PCP occurred up to 24 weeks. There were 7 nonserious and 2 serious adverse events, including 2 nonserious adverse events possibly related to…
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.